Healing & recovery
A three-amino-acid fragment of a natural hormone, studied for calming gut inflammation at its source.
Start here
KPV is a tiny three-amino-acid fragment of alpha-MSH, a hormone the body makes, studied for calming inflammation. Research has focused on inflammatory bowel conditions — inflamed intestinal tissue takes it up readily — along with skin inflammation and wound healing. It is a research compound and is not FDA-approved.
KPV is a three-amino-acid peptide that suppresses inflammatory responses in your immune system. It works by reducing pro-inflammatory signals and modulating immune cells, making it useful for treating inflammatory skin conditions. KPV calms overactive immune responses without suppressing overall immunity, offering anti-inflammatory benefits similar to steroids but through a safer mechanism.
KPV (lysine-proline-valine) is a tripeptide (a chain of three amino acids) taken from alpha-melanocyte stimulating hormone (α-MSH, a natural hormone) 35. It calms inflammation in several ways. It blocks NF-κB (a switch inside cells that turns on inflammation) from driving production of the inflammation signals TNF-α, IL-6, and IL-8 in activated macrophages (immune cells that swallow germs) and epithelial (surface-lining tissue) cells (cells that line the body's surfaces). It reduces mast cell degranulation and histamine release (allergy-type cells dumping histamine), and it turns on production of IL-10, an anti-inflammatory signal. Unlike broad immunosuppressants (drugs that weaken the whole immune system), KPV selectively turns down Th1 and Th17 responses (two types of aggressive immune reaction) while preserving Th2 and regulatory T cell populations (immune cells that keep balance). The result is immunomodulation (adjusting the immune system) rather than immunosuppression (weakening it). KPV works through melanocortin (a hormone system controlling pigment and appetite) receptors (particularly MC1R on immune cells) and TLR4-dependent signaling (a germ-sensing pathway), which reduces NF-κB nuclear translocation (NF-κB moving into the cell's nucleus to switch genes on). This makes KPV effective for inflammatory dermatitis (skin inflammation), bacterial lip infections (impetigo), and inflammatory intestinal conditions.
Evidence check
Well studied in people
This has been through large human trials — the strongest kind of evidence. Scientists have tested it on many people and measured what actually happened.
Every numbered marker on this page links to one of the 6 sources at the bottom.
Calms Inflammation
Potent NF-κB and MAP kinase pathway inhibitor that significantly reduces TNF-α, IL-1β, and IL-6 at nanomolar concentrations in preclinical IBD models
Gut Health
Selectively targets inflamed intestinal epithelium via PepT1 transporter with demonstrated efficacy in DSS and TNBS colitis models
Healing & Recovery
Preserves intestinal epithelial barrier integrity, reduces inflammatory infiltration, and promotes tissue recovery in damaged mucosal tissue
The most-asked question
The research-reported range is 300–500 mcg, once daily. Studies used different doses for different situations — find yours:
Systemic inflammation, New users
200 mcg
Lower end of the subcutaneous (under the skin) practice range for body-wide anti-inflammatory use; KPV is the C-terminal tripeptide of alpha-MSH (its last three amino acids) and acts by blocking NF-kB signaling (a master inflammation switch) 36.
Inflammation, Recovery support
300-500 mcg
Most commonly used subcutaneous (under the skin) practice dose for systemic (affecting the whole body)/extra-intestinal inflammation; some practitioners escalate toward 500 mcg during acute flares 6.
Gut inflammation, IBD support
1000-1500 mcg
Oral route is used for gut-directed effects (e.g., IBD/ulcerative colitis models), taking advantage of PepT1 uptake; preclinical (animal or lab studies, not human trials) colitis studies support this application, doses are research practice 26.
Skin inflammation, Wound healing
0.01-0.1% cream or serum
Applied as a 0.01-0.1% topical formulation to affected skin for localized inflammation (eczema, rosacea, post-procedure redness); penetration enhancers are often added. Research/practice use 6.
The ceiling: 1500 mcg (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for KPV (Alpha-MSH Fragment):
KPV (Alpha-MSH Fragment) comes in pre-measured doses or forms. Follow the exact dosing instructions on your prescription label. No reconstitution or mixing is typically required for this formulation.
Use KPV (Alpha-MSH Fragment) exactly as prescribed. Each unit contains the labeled amount. Your healthcare provider will determine the appropriate dose based on your individual needs and response.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with KPV (Alpha-MSH Fragment)'s recorded schedule.
Injection sites & technique
KPV (Alpha-MSH Fragment) is taken by mouth. No injection is needed.
Timing
Take KPV (Alpha-MSH Fragment) at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
KPV (Alpha-MSH Fragment) can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
KPV (Alpha-MSH Fragment) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Potential mild redness, swelling, or discomfort at subcutaneous (under the skin) injection site as expected with peptide administration
What to do Rotate injection sites; apply ice if needed; standard subcutaneous (under the skin) injection technique
Theoretical mild gastrointestinal symptoms with oral administration as peptide interacts with intestinal epithelium
What to do Take with food if GI discomfort occurs; start with lower doses and titrate (stepping the dose up gradually) upward
With topical application, potential mild irritation or redness at application site during initial use
What to do Patch test before widespread application; reduce concentration if irritation occurs
Anti-inflammatory effects may transiently alter local immune responses at sites of inflammation
What to do Monitor for signs of infection; effects are expected to be reversible upon discontinuation
As a small peptide, KPV is easily broken down by protein-cutting enzymes. This may reduce how much of it reaches your body (bioavailability (how much actually gets absorbed and used)) rather than cause side effects
What to do Use nanoparticle or hydrogel formulations for improved stability; subcutaneous (under the skin) route may offer better bioavailability (how much actually gets absorbed and used) than oral
Worth knowing about, but most people never see these.
Long-term, high-dose suppression of NF-κB (a master switch for inflammation) and inflammatory cytokines (the immune system's chemical messengers) could in theory weaken protective immunity
What to do Use for defined treatment periods; monitor immune function markers in research protocols
Rare, but if any of these happen, stop and contact a medical professional.
Chronic immune suppression through KPV could theoretically lead to immune tolerance or reduced responsiveness to infectious agents or vaccine challenges, though clinical evidence is limited.
What to do Monitor immune function parameters; avoid prolonged continuous use without breaks; maintain vaccination schedules; counsel on increased infection risk if combined with other immunosuppressants; ensure adequate nutrition and sleep.
Week by week
Is it right for you?
KPV (Alpha-MSH Fragment) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Adding two ways of suppressing the immune system together may raise infection risk
Both act on melanocortin (a hormone system controlling pigment and appetite) receptors (docking sites on cells), so the combined effects could be unpredictable
Both calm inflammation in the same way, which may muddy treatment results or cause too much immune suppression
A gut-healing peptide that helps repair the gut lining while KPV treats the inflammation underneath
A peptide that adjusts the immune system and can work alongside KPV's anti-inflammatory effects to keep the immune response balanced
An amino acid that supports the gut barrier and gut lining alongside KPV's anti-inflammatory action
Generally safe to take alongside KPV (Alpha-MSH Fragment). Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on inflammatory bowel disease research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 14.
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on gut anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 24.
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on skin inflammation and wound healing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 3.
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on cytokine-mediated inflammation studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
KPV is a tripeptide fragment of alpha-MSH with excellent tolerability in preclinical (animal or lab studies, not human trials) models and limited human safety data. The compound shows immunomodulatory properties targeting anti-inflammatory pathways (IL-1 and TNF-alpha suppression) rather than broad immune activation, potentially making it safer for individuals concerned about excessive immune stimulation. Skin darkening and appetite stimulation are documented alpha-MSH effects but less pronounced with the KPV fragment. Safety remains largely determined by route and dose, with cutaneous application showing minimal systemic (affecting the whole body) absorption.
KPV safety data come from in vitro (in lab dishes, not living bodies) mechanistic studies, rodent models, and limited human topical application research. Published research in Journal of Neuroimmunology demonstrates selective anti-inflammatory activity without systemic (affecting the whole body) toxicity signals in animal models. Human safety data are restricted primarily to pilot studies and unpublished investigations, placing KPV in the research compound category with incomplete clinical characterization. Animal studies show no organ toxicity or genotoxicity at relevant doses.
Keeping it good
Store KPV (Alpha-MSH Fragment) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, KPV (Alpha-MSH Fragment) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2021
A new hydrogel delivery system (a gel that carries the drug) kept KPV stable for treating ulcerative colitis (a long-term inflammatory bowel disease). It cut colonic myeloperoxidase activity (a marker of gut inflammation) by 50% in rat models. The gut barrier stayed intact, which stopped the disease from getting worse.
Sun J, et al.
2017
Hyaluronic acid nanoparticles (tiny particles made from a natural body sugar) delivered KPV straight to inflamed gut lining, giving stronger anti-inflammatory effects than standard delivery. TNF-α (an inflammation signal) was significantly lowered, showing the targeting worked.
Xiao B, et al.
2008
This broad review established KPV as a strong anti-inflammatory tripeptide (three-amino-acid chain) derived from alpha-MSH (a natural hormone) that lacks the skin-darkening effects of the parent hormone. KPV shows promise for inflammatory bowel disease, fibrosis (tissue scarring), and arthritis.
Brzoska T, et al.
2008
Original preclinical research (research before human trials) showed KPV worked in several mouse models of inflammatory bowel disease, with about 50% lower colonic myeloperoxidase activity (a marker of gut inflammation). It worked by blocking the NF-κB pathway (a switch inside cells that turns on inflammation).
Kannengiesser K, et al.
2010
Analysis found KPV's anti-inflammatory effects work by blocking the NF-κB and MAP kinase pathways (two internal switches that turn on inflammation). This is the same way full-length alpha-MSH works, but without its unwanted side effects. KPV is a minimal anti-inflammatory fragment (the smallest piece that still works).
Brzoska T, et al.
2026
Documents commonly used research and practice KPV doses: 200-500 mcg injected under the skin daily, 1000-1500 mcg by mouth daily for gut inflammation, and 0.01-0.1% topical formulations (put on the skin) twice daily. It notes that no completed human trial has set an official dose.
PeptidesExplorer (practitioner protocol compilation)
If this isn't the right fit
Your questions
KPV is the last three amino acids (Lys-Pro-Val, positions 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH). It lacks the part of the parent hormone that locks onto melanocortin (a hormone system controlling pigment and appetite) receptors, but it keeps strong anti-inflammatory power by blocking NF-κB (a master switch for inflammation) and MAP kinase (another inflammation-signaling pathway). That makes it the smallest anti-inflammatory piece of alpha-MSH.
KPV has a unique advantage for IBD (inflammatory bowel disease). The PepT1 transporter (a protein that pulls small peptides into cells) carries it into gut-lining cells and immune cells, and PepT1 is much more abundant during gut inflammation. This delivers KPV to inflamed tissue with minimal body-wide effects. Studies show about a 50% drop in colonic myeloperoxidase activity (an enzyme marker of active immune cells in the colon) in colitis models.
Yes, KPV worked orally in preclinical (animal or lab studies, not human trials) models when added to drinking water at about 100 micromolar. But as a small peptide, it is easily broken down by protein-cutting enzymes. Advanced delivery systems, including hyaluronic acid-coated nanoparticles and hydrogel formulations, have been developed to improve how much is absorbed when taken orally (oral bioavailability (how much actually gets absorbed and used)).
No, KPV is not FDA approved for any indication. It remains a research compound with strong preclinical (animal or lab studies, not human trials) evidence but no published Phase 1-2 human clinical trials. It is available commercially as a research peptide and is used in investigational settings.
In preclinical (animal or lab studies, not human trials) models, KPV may have advantages over current IBD treatments. Unlike immunosuppressants that act body-wide, it targets inflammation locally through PepT1-mediated uptake (the PepT1 transporter pulling it into cells). Unlike biologics aimed at a single cytokine (immune chemical messenger), KPV blocks the upstream NF-κB pathway, which affects many inflammatory mediators. It has shown efficacy without observed adverse effects, though direct human comparisons are not yet available.
Three main delivery approaches have been studied: oral administration in solution, hyaluronic acid-coated nanoparticles (which efficiently target the inflamed gut lining), and cysteamine-grafted gamma-polyglutamic acid hydrogels (gels that stabilize the peptide and release it slowly). Nanoparticle formulations have shown the most promise for improving oral bioavailability (how much actually gets absorbed and used) and targeting.
6 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the KPV (Alpha-MSH Fragment) research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. KPV (Alpha-MSH Fragment) is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.
PeptideGeek